CorMedix Inc. (CRMD): Price and Financial Metrics


CorMedix Inc. (CRMD): $4.92

0.17 (+3.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 508

in industry

CRMD POWR Grades


  • CRMD scores best on the Sentiment dimension, with a Sentiment rank ahead of 82.48% of US stocks.
  • CRMD's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • CRMD ranks lowest in Quality; there it ranks in the 0th percentile.

CRMD Stock Summary

  • CRMD's price/sales ratio is 764.26; that's higher than the P/S ratio of 99.19% of US stocks.
  • With a year-over-year growth in debt of 53,531.8%, CorMedix Inc's debt growth rate surpasses 99.91% of about US stocks.
  • In terms of volatility of its share price, CRMD is more volatile than 94.49% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to CorMedix Inc, a group of peers worth examining would be BILL, JKHY, GLPG, MMYT, and TYL.
  • Visit CRMD's SEC page to see the company's official filings. To visit the company's web site, go to www.cormedix.com.

CRMD Valuation Summary

  • CRMD's price/sales ratio is 1004.1; this is 8746.7% higher than that of the median Healthcare stock.
  • CRMD's price/sales ratio has moved NA NA over the prior 138 months.
  • Over the past 138 months, CRMD's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for CRMD.

Stock Date P/S P/B P/E EV/EBIT
CRMD 2021-08-31 1004.1 3.2 -10.0 -6.7
CRMD 2021-08-30 968.6 3.1 -9.7 -6.4
CRMD 2021-08-27 978.0 3.1 -9.8 -6.5
CRMD 2021-08-26 940.4 3.0 -9.4 -6.1
CRMD 2021-08-25 976.3 3.1 -9.7 -6.5
CRMD 2021-08-24 988.6 3.2 -9.9 -6.6

CRMD Growth Metrics

  • Its year over year revenue growth rate is now at 30.89%.
  • The 2 year net income to common stockholders growth rate now stands at 52.74%.
  • Its 3 year net income to common stockholders growth rate is now at -28.91%.
CRMD's revenue has moved up $51,558 over the prior 15 months.

The table below shows CRMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.245186 -23.02867 -24.53757
2021-03-31 0.253438 -20.69152 -23.68705
2020-12-31 0.239231 -21.96764 -22.02768
2020-09-30 0.208295 -19.91886 -21.24492
2020-06-30 0.174805 -16.5703 -19.90902
2020-03-31 0.193628 -15.65148 -16.82276

CRMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRMD has a Quality Grade of F, ranking ahead of 0.44% of graded US stocks.
  • CRMD's asset turnover comes in at 0.004 -- ranking 418th of 680 Pharmaceutical Products stocks.
  • INFI, ADAP, and FBRX are the stocks whose asset turnover ratios are most correlated with CRMD.

The table below shows CRMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 0.132 -5.939
2021-03-31 0.005 0.141 -8.398
2020-12-31 0.007 0.144 -6.360
2020-09-30 0.007 0.070 -5.242
2020-06-30 0.006 -0.103 -3.741
2020-03-31 0.007 -0.006 -2.141

CRMD Price Target

For more insight on analysts targets of CRMD, see our CRMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.25 Average Broker Recommendation 1.5 (Moderate Buy)

CRMD Stock Price Chart Interactive Chart >

Price chart for CRMD

CRMD Price/Volume Stats

Current price $4.92 52-week high $18.80
Prev. close $4.75 52-week low $4.36
Day low $4.58 Volume 317,100
Day high $5.01 Avg. volume 615,645
50-day MA $5.18 Dividend yield N/A
200-day MA $7.79 Market Cap 187.38M

CorMedix Inc. (CRMD) Company Bio


CorMedix Inc., a commercial pharmaceutical and medical device company, intends to in-license, develop, and commercialize prophylactic and therapeutic for the prevention and treatment of infectious and inflammatory diseases. The company was founded in 2006 and is based in Bridgewater, New Jersey.


CRMD Latest News Stream


Event/Time News Detail
Loading, please wait...

CRMD Latest Social Stream


Loading social stream, please wait...

View Full CRMD Social Stream

Latest CRMD News From Around the Web

Below are the latest news stories about CorMedix Inc that investors may wish to consider to help them evaluate CRMD as an investment opportunity.

CorMedix Inc. Announces Abstracts at Upcoming Conferences Showing Patient Outcomes and Economic Burden of CRBSI

BERKELEY HEIGHTS, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the acceptance for presentation of three abstracts at industry conferences. These include one abstract presented today at the Association of Managed Care Pharmacy (AMCP) Nexus conference in Denver, Colorado, and two abstracts being

Yahoo | October 20, 2021

CorMedix Inc. Announces Executive Leadership Changes

BERKELEY HEIGHTS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced changes to its executive leadership team. Khoso Baluch is retiring from his role as Chief Executive Officer, effective October 4, 2021, and has also resigned from the Company’s Board of Directors. John Armstrong, EVP for Technical O

Yahoo | October 4, 2021

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021. AWG members are presenting a total of 23 poster presentations and 3 oral abstract presentations.

Yahoo | September 30, 2021

LAWSUITS FILED AGAINST CRMD, ATVI and YALA - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / September 20, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.

Yahoo | September 20, 2021

SHAREHOLDER ALERT: CRMD SLQT SPPI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / September 20, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Yahoo | September 20, 2021

Read More 'CRMD' Stories Here

CRMD Price Returns

1-mo 5.58%
3-mo -21.28%
6-mo -42.59%
1-year -13.07%
3-year -12.14%
5-year -53.36%
YTD -33.78%
2020 2.06%
2019 12.87%
2018 158.00%
2017 -67.32%
2016 -24.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8213 seconds.